<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531973</url>
  </required_header>
  <id_info>
    <org_study_id>LITE Randomized Pilot Study</org_study_id>
    <nct_id>NCT00531973</nct_id>
  </id_info>
  <brief_title>A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging</brief_title>
  <acronym>LITE</acronym>
  <official_title>Liposomal Doxorubicin-Investigational Chemotherapy-Tissue Doppler Imaging Evaluation (LITE) Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized LITE study will compare liposomal doxorubin versus standard epirubicin in the
      treatment of female breast cancer. In order to detect as early as possible post-chemotherapy
      cardiotoxicity, tissue Doppler imaging parameters elicited at transthoracic echocardiography
      will be used and will constitute the primary and co-primary end-points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomized LITE study will compare liposomal doxorubin versus standard epirubicin within
      a comprehensive adjuvant or neo-adjuvant chemotherapy regimen in women undergoing treatment
      for breast cancer. The study will enrol a total of 80 patients, randomized 1:1 to liposomal
      doxorubin vs epirubicin. Standard and tissue Doppler imaging parameters will be appraised at
      transthoracic echocardiography will be used and will constitute the primary and co-primary
      end-points. In addition, other efficacy and safety end-points will be appraised, including
      disease free progression.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of changes of PW-TDI systolic function parameters. The co-primary end-point ill be the comparison of changes from baseline to 12-month follow-up of PW-TDI diastolic function parameters.</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of standard 2-dimensional echocardiography parameters, including LV ejection fraction, peak values of biochemical markers of cardiac damage and heart failure, ie cardiac troponin T and BNP.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epirubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
    <description>5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with age ≥18 and ≤65 years

          -  histological and/or cytological diagnosis of clinically non-metastatic breast cancer
             (c/pTall, c/pNall, cM0)

          -  indication for integrated treatment with surgical intervention associated with
             adjuvant or neo-adjuvant chemotherapy, endocrinological and radiation therapy,
             including adjuvant or neo-adjuvant chemotherapy with anthracycline

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤2

          -  normal kidney, hepatic and hematological function

          -  normal LV ejection fraction at baseline (≥50%)

          -  negative pregnancy test in fecund women

        Exclusion Criteria:

          -  metastatic breast cancer

          -  past radiation therapy and chemotherapy

          -  hypertension and other cardiovascular risk factors

          -  prior valvular heart disease

          -  cardiomyopathy

          -  chronic or acute congestive heart failure

          -  LV systolic dysfunction (ejection fraction&lt;50%)

          -  abnormal complete blood count

          -  pregnancy

          -  breast-feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marzia Lotrionte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>marzial76@yahoo.it</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marzia Lotrionte, MD</last_name>
    <phone>+39-3470717591</phone>
    <email>marzial76@yahoo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marzia Lotrionte, MD</last_name>
      <phone>+39-3470717591</phone>
      <email>marzial76@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Marzia Lotrionte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marzia Lotrionte, Consultant</name_title>
    <organization>Catholic University</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>echocardiography</keyword>
  <keyword>neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

